Therefore, a phase I study of DCR-MYC in patients with solid tumors and hematological malignancies was started by Dicerna Pharmaceuticals, delivering the drug by IV infusion (NCT 02110563, 2014, “Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma”). The gene discussed is MYC; the disease is AL amyloidosis.